SG10201913835XA - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor - Google Patents
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitorInfo
- Publication number
- SG10201913835XA SG10201913835XA SG10201913835XA SG10201913835XA SG10201913835XA SG 10201913835X A SG10201913835X A SG 10201913835XA SG 10201913835X A SG10201913835X A SG 10201913835XA SG 10201913835X A SG10201913835X A SG 10201913835XA SG 10201913835X A SG10201913835X A SG 10201913835XA
- Authority
- SG
- Singapore
- Prior art keywords
- administering
- inhibitor
- methods
- specific immunotherapy
- treating allergy
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 239000013566 allergen Substances 0.000 title 1
- 208000026935 allergic disease Diseases 0.000 title 1
- 230000007815 allergy Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361830919P | 2013-06-04 | 2013-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913835XA true SG10201913835XA (en) | 2020-03-30 |
Family
ID=51023185
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709670XA SG10201709670XA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
SG10201913835XA SG10201913835XA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
SG11201509044QA SG11201509044QA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709670XA SG10201709670XA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201509044QA SG11201509044QA (en) | 2013-06-04 | 2014-06-03 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor |
Country Status (26)
Country | Link |
---|---|
US (5) | US10392439B2 (fr) |
EP (2) | EP3004166B1 (fr) |
JP (5) | JP6499167B2 (fr) |
KR (3) | KR102492826B1 (fr) |
CN (3) | CN118001391A (fr) |
AU (3) | AU2014275094C1 (fr) |
CA (1) | CA2914203C (fr) |
CY (1) | CY1124095T1 (fr) |
DK (1) | DK3004166T3 (fr) |
ES (1) | ES2767080T3 (fr) |
HK (1) | HK1216898A1 (fr) |
HR (1) | HRP20200185T1 (fr) |
HU (1) | HUE048655T2 (fr) |
IL (2) | IL273678B1 (fr) |
LT (1) | LT3004166T (fr) |
MX (2) | MX2015016473A (fr) |
NZ (1) | NZ630183A (fr) |
PL (1) | PL3004166T3 (fr) |
PT (1) | PT3004166T (fr) |
RS (1) | RS59883B1 (fr) |
RU (1) | RU2679920C2 (fr) |
SG (3) | SG10201709670XA (fr) |
SI (1) | SI3004166T1 (fr) |
TW (3) | TWI633891B (fr) |
WO (1) | WO2014197470A1 (fr) |
ZA (1) | ZA201508174B (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
IN2015KN00414A (fr) | 2012-08-21 | 2015-07-17 | Sanofi Sa | |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
RS59354B1 (sr) | 2013-06-21 | 2019-10-31 | Sanofi Biotechnology | Postupci lečenja nosne polipoze davanjem il-4r antagonista |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
IL294554B2 (en) | 2014-11-14 | 2023-11-01 | Regeneron Pharma | Methods for treating chronic sinusitis with nasal polyps by adding an IL-4R antagonist |
WO2016156588A1 (fr) * | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Anticorps contre le récepteur alpha de l'interleukine 4 canine |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
JP7008020B2 (ja) * | 2015-12-18 | 2022-01-25 | インターベット インターナショナル ベー. フェー. | ヒトおよびイヌil-4rアルファに対するイヌ化ヒト抗体 |
AU2017220184B2 (en) * | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
WO2018034885A1 (fr) | 2016-08-16 | 2018-02-22 | Regeneron Pharmaceuticals, Inc. | Procédés de quantification d'anticorps individuels à partir d'un mélange. |
EP3506931A1 (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
BR112019005179A2 (pt) | 2016-09-16 | 2019-07-02 | Dyax Corp | método e kit para analisar uma amostra |
DK3532838T3 (da) | 2016-10-25 | 2022-07-04 | Regeneron Pharma | Fremgangsmåder og systemer til kromatografidataanalyse |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
WO2019028367A1 (fr) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles active |
MA46269A (fr) | 2017-08-18 | 2019-07-31 | Regeneron Pharma | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
CN111465848B (zh) | 2017-12-13 | 2023-11-28 | 里珍纳龙药品有限公司 | 管理层析柱床支架的装置和系统及相关方法 |
WO2019148405A1 (fr) * | 2018-02-01 | 2019-08-08 | 北京凯因科技股份有限公司 | ANTICORPS D'IL-4Rα ET SON UTILISATION |
CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
MX2020011172A (es) * | 2018-04-25 | 2021-01-29 | Kiniksa Pharmaceuticals Ltd | Tratamiento de enfermedades o trastornos de la piel mediante el suministro de anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta). |
TWI814812B (zh) | 2018-05-02 | 2023-09-11 | 美商里珍納龍藥品有限公司 | 用於評估生化過濾器的適合性的方法 |
CN112153982A (zh) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
WO2020014358A1 (fr) * | 2018-07-10 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Modification de molécules de liaison pour réduire au minimum des interactions préexistantes |
CN113164593A (zh) * | 2018-09-14 | 2021-07-23 | 金德雷德生物科学股份有限公司 | 兽用抗il4受体抗体 |
CN113166259A (zh) * | 2018-11-09 | 2021-07-23 | 亚洲大学校产学协力团 | 对人IL-4受体α具有高亲和力的人抗体及其用途 |
CN111514292B (zh) * | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
AU2019412405A1 (en) * | 2018-12-27 | 2021-09-02 | Akeso Biopharma, Inc | Antibody against human IL-4RA and use thereof |
RU2700788C1 (ru) * | 2019-01-17 | 2019-09-23 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ оценки эффективности проведения аллерген-специфической иммунотерапии при аллергическом рините |
BR112021018627A2 (pt) | 2019-03-21 | 2021-11-23 | Regeneron Pharma | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia |
KR20220042217A (ko) | 2019-08-05 | 2022-04-04 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법 |
CA3161037A1 (fr) | 2019-12-09 | 2021-06-17 | Sanofi Biotechnology | Methodesde traitement de troubles associes a l'il-4/il-13 identifies numeriquement |
EP3992974A1 (fr) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Procédés pour le traitement de troubles liés à l'il-13/il-4 identifiés numériquement |
CN113527485A (zh) * | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
US20230279124A1 (en) * | 2020-07-17 | 2023-09-07 | Gi Innovation, Inc. | Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof |
WO2022150605A1 (fr) * | 2021-01-08 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'allergie à l'arachide et d'amélioration de l'immunothérapie spécifique aux allergènes de l'arachide par l'administration d'un antagoniste de il-4 r |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (fr) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Recepteurs d'interleukine-4 |
CA2108886A1 (fr) | 1991-05-03 | 1992-11-04 | Thasia G. Woodworth | Molecules dirigees contre les recepteurs a interleukine pour le traitement de l'arthrite inflammatoire |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (fr) | 1992-12-29 | 1994-07-06 | Schering-Plough | Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant |
RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
US6598603B1 (en) | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
AU766492B2 (en) | 1998-09-18 | 2003-10-16 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
MXPA02011682A (es) | 2000-05-26 | 2003-05-14 | Immunex Corp | Uso de antagonistas de interleuquina-4 y composiciones de los mismos. |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
EP1304115B1 (fr) | 2000-07-26 | 2007-09-12 | Hououdou Co. Ltd. | Compositions antipruritiques et compositions favorisant la cicatrisation des blessures |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
EP1390067A1 (fr) | 2001-05-11 | 2004-02-25 | Novartis AG | Compositions permettant de traiter les troubles associes aux ige |
DK1450855T3 (da) | 2001-05-23 | 2010-01-11 | Duotol Ab | Undertrykkelse af allergiske reaktioner ved hjælp af transdermal indgivelse af allergener i forbindelse med eller konjugeret til toxin-underenheder eller fragmenter deraf |
EP2990394A1 (fr) | 2001-11-30 | 2016-03-02 | Biogen MA Inc. | Anticorps dirigés contre des protéines chimiotactiques |
ATE435239T1 (de) | 2002-03-29 | 2009-07-15 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
WO2004047793A1 (fr) | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Produit pharmaceutique comprenant des allergenes |
CN102993306B (zh) | 2003-02-01 | 2015-01-28 | 唐纳士公司 | 高亲和力抗人类IgE抗体 |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
CA2543982C (fr) * | 2003-11-07 | 2013-01-08 | Immunex Corporation | Anticorps liant un recepteur de l'interleucine 4 |
AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
WO2005085284A1 (fr) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | Polypeptides specifiques d'il-4/il-13 et utilisations therapeutiques associees |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
WO2006083390A2 (fr) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxine-3 dans l'oesophagite eosinophile |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
ES2466669T3 (es) | 2006-10-02 | 2014-06-10 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
DK2132230T3 (da) | 2007-03-22 | 2014-06-30 | Genentech Inc | Apoptotiske anti-ige-antistoffer, der binder det membranbundne ige |
EP2022507A1 (fr) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique |
US8637239B2 (en) | 2007-11-05 | 2014-01-28 | The Board Of Trustees Of The University Of Illinois | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
WO2010065557A2 (fr) | 2008-12-01 | 2010-06-10 | Cincinnati Children's Hospital Medical Center | Procédés de détermination de l'efficacité d'un traitement par glucocorticoïde de l'oesophagite à éosinophiles |
WO2010120511A2 (fr) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Procédé de traitement de troubles respiratoires |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
CN102596237A (zh) | 2009-09-07 | 2012-07-18 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
ES2894936T3 (es) | 2010-06-24 | 2022-02-16 | Viropharma Biologics Llc | Métodos de tratamiento para la inflamación del esófago |
EP3354280B1 (fr) | 2010-10-06 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisées contenant des anticorps anti-récepteur de l'interleukine-4 (il-4r) |
RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
US20130324435A1 (en) | 2011-01-06 | 2013-12-05 | Children's Hospital Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
WO2012177945A2 (fr) | 2011-06-21 | 2012-12-27 | Children's Hospital Medical Center | Méthodes de diagnostic pour œsophagite à éosinophiles |
WO2013051928A1 (fr) | 2011-10-06 | 2013-04-11 | N.V. Nutricia | Traitement de l'œsophagite à éosinophiles |
WO2013088109A1 (fr) | 2011-12-16 | 2013-06-20 | Oxagen Limited | Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l'œsophagite à éosinophiles |
WO2013155010A1 (fr) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Biomarqueurs non invasifs pour l'œsophagite éosinophile |
IN2015KN00414A (fr) | 2012-08-21 | 2015-07-17 | Sanofi Sa | |
EP4374919A2 (fr) * | 2012-09-07 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de la dermatite atopique par administration d'un antagoniste de l'il-4r |
US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
EP3620468A1 (fr) | 2013-02-05 | 2020-03-11 | EngMab Sàrl | Procédé de sélection d'anticorps contre bcma |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
RS59354B1 (sr) | 2013-06-21 | 2019-10-31 | Sanofi Biotechnology | Postupci lečenja nosne polipoze davanjem il-4r antagonista |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
PL3107575T3 (pl) | 2014-02-21 | 2022-01-17 | Sanofi Biotechnology | Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R |
CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
IL294554B2 (en) | 2014-11-14 | 2023-11-01 | Regeneron Pharma | Methods for treating chronic sinusitis with nasal polyps by adding an IL-4R antagonist |
AU2017220184B2 (en) | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
EP3506931A1 (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
IL310371A (en) | 2016-09-22 | 2024-03-01 | Regeneron Pharma | Methods for treating severe allergic dermatitis by administering an il-4r inhibitor |
WO2018151836A1 (fr) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Traitements d'association pour le traitement de cancers associés à bcma et de troubles auto-immuns |
EP3615068A1 (fr) | 2017-04-28 | 2020-03-04 | Novartis AG | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
WO2019028367A1 (fr) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles active |
MA46269A (fr) | 2017-08-18 | 2019-07-31 | Regeneron Pharma | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
CN112153982A (zh) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 |
BR112021018627A2 (pt) | 2019-03-21 | 2021-11-23 | Regeneron Pharma | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia |
KR20220042217A (ko) | 2019-08-05 | 2022-04-04 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법 |
SG11202113310UA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
CA3161037A1 (fr) | 2019-12-09 | 2021-06-17 | Sanofi Biotechnology | Methodesde traitement de troubles associes a l'il-4/il-13 identifies numeriquement |
KR20230015965A (ko) | 2020-05-22 | 2023-01-31 | 리제너론 파아마슈티컬스, 인크. | Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법 |
-
2014
- 2014-05-30 TW TW103118916A patent/TWI633891B/zh active
- 2014-05-30 TW TW109120861A patent/TWI755763B/zh active
- 2014-05-30 TW TW107126334A patent/TWI697334B/zh active
- 2014-06-03 US US14/294,544 patent/US10392439B2/en active Active
- 2014-06-03 HU HUE14733922A patent/HUE048655T2/hu unknown
- 2014-06-03 WO PCT/US2014/040695 patent/WO2014197470A1/fr active Application Filing
- 2014-06-03 CN CN202410184651.4A patent/CN118001391A/zh active Pending
- 2014-06-03 LT LTEP14733922.0T patent/LT3004166T/lt unknown
- 2014-06-03 NZ NZ630183A patent/NZ630183A/en unknown
- 2014-06-03 DK DK14733922.0T patent/DK3004166T3/da active
- 2014-06-03 KR KR1020227001662A patent/KR102492826B1/ko active IP Right Grant
- 2014-06-03 CN CN202410184683.4A patent/CN117982639A/zh active Pending
- 2014-06-03 SG SG10201709670XA patent/SG10201709670XA/en unknown
- 2014-06-03 KR KR1020157034008A patent/KR102355114B1/ko active Application Filing
- 2014-06-03 SG SG10201913835XA patent/SG10201913835XA/en unknown
- 2014-06-03 IL IL273678A patent/IL273678B1/en unknown
- 2014-06-03 MX MX2015016473A patent/MX2015016473A/es unknown
- 2014-06-03 SI SI201431427T patent/SI3004166T1/sl unknown
- 2014-06-03 ES ES14733922T patent/ES2767080T3/es active Active
- 2014-06-03 RU RU2015156628A patent/RU2679920C2/ru active
- 2014-06-03 RS RS20200093A patent/RS59883B1/sr unknown
- 2014-06-03 PL PL14733922T patent/PL3004166T3/pl unknown
- 2014-06-03 AU AU2014275094A patent/AU2014275094C1/en active Active
- 2014-06-03 CN CN201480032190.3A patent/CN105377894A/zh active Pending
- 2014-06-03 CA CA2914203A patent/CA2914203C/fr active Active
- 2014-06-03 PT PT147339220T patent/PT3004166T/pt unknown
- 2014-06-03 EP EP14733922.0A patent/EP3004166B1/fr active Active
- 2014-06-03 SG SG11201509044QA patent/SG11201509044QA/en unknown
- 2014-06-03 KR KR1020237002686A patent/KR102580468B1/ko active IP Right Grant
- 2014-06-03 EP EP19202527.8A patent/EP3617233A1/fr active Pending
- 2014-06-03 JP JP2016518408A patent/JP6499167B2/ja active Active
-
2015
- 2015-11-04 ZA ZA2015/08174A patent/ZA201508174B/en unknown
- 2015-11-04 IL IL242456A patent/IL242456B/en active IP Right Grant
- 2015-11-30 MX MX2021002173A patent/MX2021002173A/es unknown
-
2016
- 2016-04-25 HK HK16104712.1A patent/HK1216898A1/zh unknown
-
2017
- 2017-12-14 US US15/842,865 patent/US10669341B2/en active Active
- 2017-12-14 US US15/842,868 patent/US10676530B2/en active Active
-
2019
- 2019-03-13 JP JP2019045324A patent/JP6754857B2/ja active Active
- 2019-06-27 AU AU2019204577A patent/AU2019204577B2/en active Active
-
2020
- 2020-02-05 HR HRP20200185TT patent/HRP20200185T1/hr unknown
- 2020-02-10 CY CY20201100122T patent/CY1124095T1/el unknown
- 2020-04-24 US US16/858,488 patent/US11485788B2/en active Active
- 2020-08-21 JP JP2020139935A patent/JP7061163B2/ja active Active
-
2021
- 2021-09-10 AU AU2021229250A patent/AU2021229250A1/en active Pending
-
2022
- 2022-04-14 JP JP2022066688A patent/JP7284313B2/ja active Active
- 2022-09-23 US US17/935,003 patent/US20230159647A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081214A patent/JP2023103389A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273678A (en) | Methods for treating allergy and improving allergen-specific immunotherapy by administering an il-4r inhibitor | |
IL274464A (en) | Preparations and methods for the detection of rare sequence variants | |
HK1224140A1 (zh) | 轉錄因子抑制劑及其用途 | |
HK1219947A1 (zh) | 抑製劑及其用途 | |
ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
PL3637254T3 (pl) | Urządzenie przenośne i sposób ograniczania korzystania z urządzenia przenośnego | |
EP3045892A4 (fr) | Dispositif d'analyse de gaz et procédé d'analyse de gaz | |
EP2972313A4 (fr) | Chambre d'écoulement à plaques parallèles à orifices et leurs procédés d'utilisation | |
EP2967547A4 (fr) | Dispositif et procédé anastomotique | |
HK1223112A1 (zh) | 抗- -α/ 雙靶向抗體及其應用 | |
HK1224307A1 (zh) | 原毒素- 變體及其使用方法 | |
EP2959712A4 (fr) | Procédé et système d'identification d'exceptions de comportements d'individus | |
SG2013093067A (en) | Method and system for verification of presence | |
GB201604534D0 (en) | Nucleic-acid-sequence determination device and nucleic-acid-sequence determination method | |
PL3010620T3 (pl) | Urządzenie filtracyjne i sposób odprowadzania | |
EP2964225A4 (fr) | Inhibiteurs de camkii et leurs utilisations | |
HK1216754A1 (zh) | 抗- 抗體及其使用方法 | |
EP3065038A4 (fr) | Méthode de présentation de dispositif terminal et dispositif terminal | |
SG11201600347UA (en) | Gas purge device and gas purge method | |
GB201307317D0 (en) | Valve System and Methods of Operation Thereof | |
EP3022205A4 (fr) | Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci | |
PT2769654T (pt) | Grelhador a gás e respetivo processo | |
EP2972012A4 (fr) | Dispositif compresseur et procédé associé | |
GB201315673D0 (en) | Vending apparatus and methods of vending | |
GB201312914D0 (en) | Transaction apparatus and related methods |